The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy

Page 1 of 2

As I’m sure you’ve probably heard by now, Amgen, Inc. (NASDAQ:AMGN) agreed to purchase¬†Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125 per share.

Amgen, Inc. (NASDAQ:AMGN)

While that’s certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for — at one point, after Amgen, Inc. (NASDAQ:AMGN) made its initial $120 bid, shares of the biotech topped $136 — the deal looks healthy for the sector in general.

M&A still an option for exit
Without a doubt, M&A is still the easiest way to make money in the biotech sector. Unlike the typical binary event, an acquisition only has upside potential; unless it’s a take-under, there’s no downside related to the M&A event. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors who were holding before Amgen, Inc. (NASDAQ:AMGN)’s initial bid was announced are sitting on a nice 44% increase.

Without a doubt, it’s good news for the industry that Amgen, Inc. (NASDAQ:AMGN) would go after Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and still raise its bid when it appears no one else was interested in buying the biotech. Investors in other biotechs should see an increase in value simply because there’s a possibility that they’ll be bought. I wouldn’t buy for that reason alone, but it’s nice to have a valuation bump as long as it doesn’t get out of control.

Partner shmartner
Conventional wisdom says having a big pharma partner makes a biotech less likely to be a takeout target because potential buyers won’t want to work with the partner. The most obvious buyer is the current partner, and it’s hard to get a bidding war going with just one bidder.

But Amgen, Inc. (NASDAQ:AMGN) was still willing to purchase Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), which markets Nexavar with Bayer. There’s more to Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) than Nexavar — its blood cancer drug Kyprolis was likely just as much a factor in the purchase — but the fact that Amgen, Inc. (NASDAQ:AMGN) wasn’t scared off by having to work with Bayer is a good sign for other commercial-stage biotechs with partners.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), for instance, is partnered with Eisai for their obesity drug Belviq. While I doubt anyone would be interested in buying Arena right now given the lackluster launch, if the companies can overcome the challenges of selling obesity drugs, it’s not hard to see how someone would want to buy Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). The potential obesity market is huge (pun intended).

It’ll be interesting to see how far this “partners don’t matter” thought might go. Fellow Fool, Keith Speights, suggested that Seattle Genetics, Inc. (NASDAQ:SGEN) could be next, but the company has partnerships with 12 different companies. I’m not sure a big pharma would want to deal with that many of its competitors.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!